A hard‑core breakthrough! Winning a provincial science and technology award—see how Jiangxi’s biotech sector is upgrading life‑saving clinical drugs.

Recently, the People’s Government of Jiangxi Province officially issued the “Decision on the 2025 Jiangxi Provincial Science and Technology Awards” (Gan Fa [2026] No. 8), and the list of winners for the 2025 Jiangxi Provincial Science and Technology Awards was unveiled. The project “Innovative End-to-End Technology System for High-Purity Tetanus Antitoxin and Its Industrial Application,” led by Jiangxi Biological Products Research Institute Co., Ltd. (referred to as “Jiangxi Bio”; stock code: 6915.HK), was awarded the Second Prize of the Jiangxi Provincial Technological Invention Award, becoming one of the ten provincial science and technology award-winning achievements in Ji’an City, Jiangxi Province, for 2025. This prestigious provincial-level scientific honor is a well-deserved recognition of the company’s dedicated efforts in the biopharmaceutical field, its determination to tackle the industry’s most challenging problems, and its success in achieving technological breakthroughs.

As an indispensable “protective shield” on the clinical emergency‑care front line, tetanus antitoxin (TAT) plays an irreplaceable role in trauma‑related emergency treatment. In settings such as burn injuries and blunt‑force trauma, it bears the critical responsibility of preventing tetanus infection. However, for a long time, challenges stemming from conventional manufacturing processes have plagued the industry: limited product purity, the potential for adverse reactions due to heterologous proteins, stringent viral‑safety controls, and insufficient formulation stability. These persistent pain points directly affect the medication safety of countless patients and pose a formidable hurdle for biopharmaceutical researchers.

Faced with pressing clinical needs, the company’s R&D team zeroed in on key technological bottlenecks and launched a rigorous, high‑stakes research effort. Rooted in both the laboratory and the production floor, the team built expertise from the ground up—starting with animal immunization and antigen development—then advanced through antibody purification, preservative removal, and viral inactivation processes, culminating in formulation optimization and upgraded product packaging. By systematically innovating every stage of the manufacturing process, they established a comprehensive, end-to-end innovative technology platform for high‑purity tetanus antitoxin, backed by proprietary intellectual property.

Through repeated experimentation and refinement, and successive rounds of iterative optimization, breakthrough progress has been achieved in multiple key technologies. By innovating manufacturing processes, the company has efficiently removed heterologous protein fragments that can trigger adverse reactions, resulting in a dramatic increase in product specific activity. To date, the company’s products have reached a maximum specific activity of 90,000 IU/gp, far exceeding the Chinese Pharmacopoeia’s standard of 45,000 IU/gp. Additionally, an innovative preservative‑free formulation has been developed, paired with specialized vial packaging, which not only strengthens the virus‑safety barrier but also significantly reduces the risk of adverse drug reactions in clinical use. Product storage stability has likewise been markedly improved, addressing the shortcomings of conventional formulations and filling several technological gaps in related domestic processes.

Scientific research extends beyond the laboratory; it must also translate into clinical practice and safeguard public health. Today, this innovative technology has been successfully commercialized, and its next‑generation tetanus antitoxin product—after iterative upgrades—outperforms the national pharmacopoeia standards in key metrics. It now supports trauma‑care settings across medical institutions nationwide while expanding internationally, exporting to numerous countries and contributing “Made in Jiangxi” pharmaceutical solutions to public‑health emergency response both at home and abroad, yielding significant social and economic benefits. The project has also generated a portfolio of core invention patents, serving as a remarkable milestone on the company’s journey of independent innovation.

For more than fifty years, Jiangxi Bio has remained deeply committed to the biopharmaceutical sector, consistently placing the safeguarding of public health and well-being at the forefront of its research and development efforts. This award represents the provincial Party committee and government’s high recognition of the company’s original innovation capabilities and its strength in commercializing scientific and technological achievements, while also serving as an inspiring new call to action.

Innovation never stops, and our commitment to our original mission remains unchanged. Looking ahead, the company will take this honor as a new starting point, continue to ramp up investment in research and development, focus on key technologies in the biopharmaceutical sector, boldly venture into uncharted technological territories, and accelerate the R&D and commercialization of new technologies and products. By leveraging scientific and technological innovation, we will drive high-quality growth in Jiangxi’s biopharmaceutical industry and contribute even more to the nation’s public health initiatives!